Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
學年 96
學期 1
出版（發表）日期 2008-01-01
作品名稱 Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
作品名稱（其他語言）
著者 Lane, Hsien-Yuan; Liu, Yi-Ching; Huang, Chieh-Liang; Chang, Yue-Cune; Liau, Chun-Hui; Perng, Cheng-Hwang; Tsai, Guochuan E.
單位 淡江大學數學學系
出版者 Philadelphia: Elsevier Inc.
著錄名稱、卷期、頁數 Biological Psychiatry 63(1), pp.9–12
摘要 Background Small molecules that enhance the N-methyl-D-aspartate (NMDA) neurotransmission have been shown to be beneficial as adjuvant therapy for schizophrenia. Among these compounds, sarcosine (a glycine transporter-I inhibitor), when added to an existing regimen of antipsychotic drugs, has shown its efficacy for both chronically stable and acutely ill patients. However, the efficacy of these agents as a primary antipsychotic agent has not yet been demonstrated. Methods Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily. Results Overall, patients in the 2-g group were more likely to respond as defined by a 20% or more reduction of the Positive and Negative Syndrome Scale total score, particularly among antipsychotic-naïve patients. However, there was no significant between-group difference in the sarcosine dose × time interaction analysis. Both doses were well tolerated with minimal side effects. Conclusions Although patients receiving the 2-g daily dose were more likely to respond, it requires further clarification whether the effect is limited to the antipsychotic-naive population. Future placebo- or active-controlled, larger-sized studies are needed to fully assess sarcosine’s effects.
關鍵字 Glutamate; GlyT-1; N-methyl-D-aspartate; sarcosine; schizophrenia
語言 en
ISSN 0006-3223
期刊性質 國外
收錄於 SCI
產學合作
通訊作者 Tsai, Guochuan E.
審稿制度 是
國別 USA
公開徵稿
出版型式 紙本
相關連結

機構典藏連結 ( http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/58785 )

機構典藏連結